Zhengxiang Han
机构：Xuzhou Medical College, Affiliated Hospital of Xuzhou Medical College · ORCID：0000-0003-2463-8933
发表论文 112 篇 · 总被引 1001 次 · h-index 14
代表论文
- Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 150)
- Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
- Roles and functions of tumor-infiltrating lymphocytes and tertiary lymphoid structures in gastric cancer progression (2025 · Frontiers in Immunology · 被引 13)
- Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy (2024 · World Journal of Gastroenterology · 被引 12)
- Efficacy and safety of RC48-ADC in HER2-positive and HER2-low metastatic breast cancer: a multicenter, real-world study (2024 · Frontiers in Oncology · 被引 10)
- Association of triglyceride-glucose index with long-term prognosis in advanced hepatocellular carcinoma patients receiving immunotherapy and targeted therapy (2025 · World Journal of Gastroenterology · 被引 5)